Endocrine Abstracts

Aim: To study complications in patients with acromegaly receiving somatostatin after radiotherapy.Materials and methods: We examined 16 patients with mean disease duration 8.5±4.2 years (mean age 41.5±5.6 years) receiving distant gamma-therapy in the total dose of 60 Gy. The patients were divided into two groups: eight patients receiving somatostatin in the dose of 0.5 mg thrice a day and symptomatic therapy for 2 months were included into the ...

Efficacy of the combined therapy of somatostatin analogues and dopamine receptor antagonists in patients with growth hormone (GH) producing hypophysial adenomas was compared. 30 patients with acromegalia aged from 28 to 58 with the disease duration from 2 to 5 years receiving radio – therapy (gamma-therapy, 60 Gy) within 2001–2002 were examined. 7 of the examinees (1st group) received sandostatin in the dose of 100 mkg/day and 23 patients received parlodel in the dos...

Purpose: To assess the effect of radiation therapy (RT) in patients with acromegaly, depending on the age of the patients and the activity of the formation.Materials and methods: The object of the study was 50 patients (36 women and 14 men) with acromegaly who received gamma-therapy in a total dose of 45-60 Gr. The age of patients ranged from 29 to 77 years. By age, the patients were divided into 3 groups: 1st age group-29–44years old-23patients (46...

The purpose of the study: To examine the incidence of neuroendocrine complications after RT of pituitary somatotropinomas.Materials and methods: Thirty patients surveyed after receiving radiation therapy (RT) at a dose of 45 g in 25 fractions a day. Of these, 21 (70%) females, 9 (30%) men. The age of patients ranged from 36–71 years. 37% of them had pituitary macroadenoma with para-, supra-, infrasellar growth. Duration of illness was on average 15 ...